Author: NSV
NorthSea Therapeutics announces publication of positive results from Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 MASH in Journal of Hepatology
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a private, late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases, has announced that results from the Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 metabolic dysfunction-associated steatohepatitis (MASH) were published in the Journal of Hepatology.
Read More
Ventyx Biosciences announces presentation of data from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in Crohn’s Disease at ECCO 2025
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn’s disease will be presented during the 20th Congress of
Read More
RANsemi partners with Antevia Networks to provide silicon for Open RAN Radio Units
RANsemi, a British wireless semiconductor innovator specialising in 5G Open RAN baseband technologies, has partnered with Antevia Networks for its 5G SHIFT enterprise private 5G platform. 5G SHIFT employs Open RAN (O-RAN) fronthaul technology in its Radio Units (O-RUs) running on RANsemi 5G PHY SoCs to enhance in-building wireless coverage.
Read MoreVentyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. “We believe that 2025 will be
Read More
Phase Four Series C first closing
Phase Four, a leader in advanced in-space propulsion design and manufacturing, has announced the first close of its Series C funding round, securing nearly 60% of the target raise with strong participation from new and existing investors. The round is led by Artemis Group Capital, the Oklahoma-based investment firm helmed
Read More
VORAGO Technologies and Collabora partner to advance open source in space
VORAGO Technologies, a leading provider of radiation hardened and radiation tolerant MCUs and MPUs for Aerospace and Defense, and Collabora, a leader in open source software and support, today announced they are partnering to advance the use of open source to achieve resilience for mission critical applications in space. “As
Read More
Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI
Sagence AI™ has emerged from stealth unveiling a groundbreaking advanced analog in-memory compute architecture that directly addresses the untenable power/performance/price and environmental sustainability conundrum facing AI inferencing. Driven by its industry-first architectural innovations using analog technology, Sagence AI makes possible multiple orders of magnitude improvement in energy efficiency and cost
Read MoreVentyx Biosciences announces late-breaking abstract highlighting high rates of clinical and endoscopic remission among LTE completers at Week 52
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that a late-breaking abstract including new long-term extension (LTE) data from the Phase 2 trial of tamuzimod in ulcerative
Read More
Achronix releases groundbreaking Speedster AC7t800 Mid-Range FPGA, driving innovation in AI/ML, 5G/6G and Data Center Applications
Achronix Semiconductor Corporation, a leader in FPGA-based hardware accelerator devices and high-performance eFPGA IP, has announced the availability and shipment of AC7t800 FPGA, designed to address the rapidly growing needs of data-centric applications such as generative AI, DPUs and SmartNICs. With samples available today and units already shipped to customers,
Read MoreVentyx Biosciences announces $27 million strategic investment from Sanofi
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that Sanofi has agreed to make a $27 million strategic investment in the Company at an as-converted price of
Read More
PlanetiQ awarded $6.5 Million NOAA contract to supply Radio Occultation data for the commercial weather pilot data program
PlanetiQ, a leading innovator of global atmospheric observing systems, has been awarded a Delivery Order (DO-4) contract valued at over $6.5M to supply the National Oceanic and Atmospheric Administration (NOAA) with their proprietary radio occultation (RO) data for a period of one year beginning September 18, 2024. “In addition to
Read MoreVentyx Biosciences announces initiation of dosing in a Phase 2a trial of VTX3232 in patients with early Parkinson’s disease
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson’s
Read More